Description of research

Finnish-German biochemist, high school diploma from Gymnasium An der Stenner (Iserlohn, Germany), undergraduate studies at the University of Hamburg, PhD from the University of Helsinki, Finland in 2003 with Kari Alitalo: discovery of the first growth factors for lymphatic vessels: VEGF-C and VEGF-D. Since 2020 associate professor at the Faculty of Pharmacy, University of Helsinki. Experience in three biotech startups with several patents and three drugs in clinical trials: OPT-302/sozinibercept (developer, phase III), VGX-100 and Lymfactin (co-developer, up to phase I and II, respectively). Currently working on novel and sustainable protein expression systems.

Affiliations

University of Helsinki
Unit
Translational Cancer Biology Program/Individual Drug Therapy Research Program
Molecular/Cancer Biology Laboratory
Drug Research Program
Molecular/Cancer Biology Laboratory
Title
Group leader 2013 - 2020
Postdoctoral Fellow 2003 - 2013
Associate Professor in Pharmaceutical Protein Drug Research 2020
Graduate Student 1996 - 2002
Source : ORCID

Wihuri Research Institute
Title
Postdoctoral Fellow 2013 - 2013
Source : ORCID

Vegenics Ltd/Circadian Technologies via Licentia Oy (now Opthea)
Title
Contract Researcher 2007 - 2011
Source : ORCID

Helsinki University Licencing Ltd./Licentia Ltd.
Title
Contract Researcher 1999 - 2005
Source : ORCID

Heinrich-Pette-Institut Leibniz-Institut fur Experimentelle Virologie
Unit
Group Hans Will
Title
Research Assistant 1994 - 1995
Source : ORCID

Lymphatix Oy (acquired by Ark Therapeutics)
Title
Researcher 2006 - 2007
Source : ORCID

Education

Degrees
MSc 1994 - 1997 / University of Helsinki
Baccalaureate 1980 - 1989 / Gymnasium An der Stenner
PhD 1997 - 2002 / University of Helsinki
BSc/"Vordiplom" 1990 - 1994 / University of Hamburg

Publications (80)

Expansion and collapse of VEGF diversity in major clades of the animal kingdom
2023

The Relationship between the Secondary Vascular System and the Lymphatic Vascular System in Fish
2023

Bioactive VEGF-C from E. coli
2022

Granted funding (1)

Development of a biotherapeutical to counter cancer “resistance” to presently used anti- angiogenic drugsResearch Council of Finland2013 - 2018

Activities and awards (9)

reviewerreviewer of a scientific journal2021
reviewerreviewer of a scientific journal2019
Lymphangiogenesis in Health and Diseaseconference presentation2015
Show all